Does the media prefer SANA or NAMS?

In the previous week, Sana Biotechnology had 1 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 4 mentions for Sana Biotechnology and 3 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.51 beat Sana Biotechnology's score of 0.18 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral NewAmsterdam Pharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SANA or DNLI more profitable?

Denali Therapeutics' return on equity of -52.20% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Sana Biotechnology N/A -108.01% -40.68% Denali Therapeutics N/A -52.20% -43.86%

Does the media refer more to SANA or DNLI?

In the previous week, Sana Biotechnology had 3 more articles in the media than Denali Therapeutics. MarketBeat recorded 4 mentions for Sana Biotechnology and 1 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.93 beat Sana Biotechnology's score of 0.18 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Denali Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, DYN or SANA?

Dyne Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dyne Therapeutics N/A N/A -$446.21M -$3.22 N/A Sana Biotechnology N/A N/A -$244.17M -$0.93 N/A

Is DYN or SANA more profitable?

Dyne Therapeutics' return on equity of -58.28% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Dyne Therapeutics N/A -58.28% -46.77% Sana Biotechnology N/A -108.01% -40.68%

Does the media favor DYN or SANA?

In the previous week, Dyne Therapeutics had 4 more articles in the media than Sana Biotechnology. MarketBeat recorded 8 mentions for Dyne Therapeutics and 4 mentions for Sana Biotechnology. Dyne Therapeutics' average media sentiment score of 0.59 beat Sana Biotechnology's score of 0.18 indicating that Dyne Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sana Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SANA or CPRX?

In the previous week, Catalyst Pharmaceuticals had 1 more articles in the media than Sana Biotechnology. MarketBeat recorded 5 mentions for Catalyst Pharmaceuticals and 4 mentions for Sana Biotechnology. Catalyst Pharmaceuticals' average media sentiment score of 0.87 beat Sana Biotechnology's score of 0.18 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Catalyst Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RLAY or SANA more profitable?

Relay Therapeutics' return on equity of -43.94% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Relay Therapeutics N/A -43.94% -40.11% Sana Biotechnology N/A -108.01% -40.68%

Does the media favor RLAY or SANA?

In the previous week, Relay Therapeutics had 1 more articles in the media than Sana Biotechnology. MarketBeat recorded 5 mentions for Relay Therapeutics and 4 mentions for Sana Biotechnology. Relay Therapeutics' average media sentiment score of 0.49 beat Sana Biotechnology's score of 0.18 indicating that Relay Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sana Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Sana Biotechnology (SANA) Competitors

$3.14 -0.01 (-0.32%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$3.16 +0.02 (+0.64%)

As of 05:12 AM Eastern

Compare

SANA vs. NAMS, DNLI, DYN, CPRX, and RLAY

Should you buy Sana Biotechnology stock or one of its competitors? MarketBeat compares Sana Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sana Biotechnology include NewAmsterdam Pharma (NAMS), Denali Therapeutics (DNLI), Dyne Therapeutics (DYN), Catalyst Pharmaceuticals (CPRX), and Relay Therapeutics (RLAY). These companies are all part of the "pharmaceutical products" industry.

How does Sana Biotechnology compare to NewAmsterdam Pharma?

Sana Biotechnology (NASDAQ:SANA) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

Sana Biotechnology has a beta of 2.13, meaning that its share price is 113% more volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.08, meaning that its share price is 92% less volatile than the broader market.

In the previous week, Sana Biotechnology had 1 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 4 mentions for Sana Biotechnology and 3 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.51 beat Sana Biotechnology's score of 0.18 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
NewAmsterdam Pharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sana Biotechnology presently has a consensus price target of $9.50, indicating a potential upside of 202.55%. NewAmsterdam Pharma has a consensus price target of $49.42, indicating a potential upside of 66.55%. Given Sana Biotechnology's higher possible upside, analysts clearly believe Sana Biotechnology is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

88.2% of Sana Biotechnology shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 25.4% of Sana Biotechnology shares are owned by insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Sana Biotechnology has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-108.01%	-40.68%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

NewAmsterdam Pharma has higher revenue and earnings than Sana Biotechnology. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A
NewAmsterdam Pharma	$22.50M	154.15	-$203.82M	-$1.79	N/A

Summary

NewAmsterdam Pharma beats Sana Biotechnology on 9 of the 16 factors compared between the two stocks.

How does Sana Biotechnology compare to Denali Therapeutics?

Sana Biotechnology (NASDAQ:SANA) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Sana Biotechnology has higher earnings, but lower revenue than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A
Denali Therapeutics	$330.53M	11.00	-$512.54M	-$2.88	N/A

In the previous week, Sana Biotechnology had 3 more articles in the media than Denali Therapeutics. MarketBeat recorded 4 mentions for Sana Biotechnology and 1 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.93 beat Sana Biotechnology's score of 0.18 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Denali Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sana Biotechnology presently has a consensus target price of $9.50, indicating a potential upside of 202.55%. Denali Therapeutics has a consensus target price of $35.08, indicating a potential upside of 53.20%. Given Sana Biotechnology's higher probable upside, research analysts clearly believe Sana Biotechnology is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82

Sana Biotechnology has a beta of 2.13, indicating that its share price is 113% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market.

88.2% of Sana Biotechnology shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 25.4% of Sana Biotechnology shares are held by company insiders. Comparatively, 9.7% of Denali Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Denali Therapeutics' return on equity of -52.20% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-108.01%	-40.68%
Denali Therapeutics	N/A	-52.20%	-43.86%

Summary

Sana Biotechnology beats Denali Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Sana Biotechnology compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Sana Biotechnology (NASDAQ:SANA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

Dyne Therapeutics presently has a consensus target price of $34.17, suggesting a potential upside of 45.70%. Sana Biotechnology has a consensus target price of $9.50, suggesting a potential upside of 202.55%. Given Sana Biotechnology's higher probable upside, analysts plainly believe Sana Biotechnology is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Dyne Therapeutics' return on equity of -58.28% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-58.28%	-46.77%
Sana Biotechnology	N/A	-108.01%	-40.68%

In the previous week, Dyne Therapeutics had 4 more articles in the media than Sana Biotechnology. MarketBeat recorded 8 mentions for Dyne Therapeutics and 4 mentions for Sana Biotechnology. Dyne Therapeutics' average media sentiment score of 0.59 beat Sana Biotechnology's score of 0.18 indicating that Dyne Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sana Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dyne Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A

Dyne Therapeutics has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.13, meaning that its stock price is 113% more volatile than the broader market.

96.7% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are held by institutional investors. 9.5% of Dyne Therapeutics shares are held by insiders. Comparatively, 25.4% of Sana Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Dyne Therapeutics and Sana Biotechnology tied by winning 7 of the 14 factors compared between the two stocks.

How does Sana Biotechnology compare to Catalyst Pharmaceuticals?

Sana Biotechnology (NASDAQ:SANA) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Sana Biotechnology's net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-108.01%	-40.68%
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

88.2% of Sana Biotechnology shares are held by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 25.4% of Sana Biotechnology shares are held by insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Sana Biotechnology has a beta of 2.13, indicating that its share price is 113% more volatile than the broader market. Comparatively, Catalyst Pharmaceuticals has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

Catalyst Pharmaceuticals has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A
Catalyst Pharmaceuticals	$596.96M	6.46	$214.33M	$1.74	18.10

In the previous week, Catalyst Pharmaceuticals had 1 more articles in the media than Sana Biotechnology. MarketBeat recorded 5 mentions for Catalyst Pharmaceuticals and 4 mentions for Sana Biotechnology. Catalyst Pharmaceuticals' average media sentiment score of 0.87 beat Sana Biotechnology's score of 0.18 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Catalyst Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sana Biotechnology presently has a consensus price target of $9.50, suggesting a potential upside of 202.55%. Catalyst Pharmaceuticals has a consensus price target of $32.00, suggesting a potential upside of 1.62%. Given Sana Biotechnology's stronger consensus rating and higher probable upside, research analysts clearly believe Sana Biotechnology is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56

Summary

Catalyst Pharmaceuticals beats Sana Biotechnology on 10 of the 16 factors compared between the two stocks.

How does Sana Biotechnology compare to Relay Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Sana Biotechnology (NASDAQ:SANA) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.

In the previous week, Relay Therapeutics had 1 more articles in the media than Sana Biotechnology. MarketBeat recorded 5 mentions for Relay Therapeutics and 4 mentions for Sana Biotechnology. Relay Therapeutics' average media sentiment score of 0.49 beat Sana Biotechnology's score of 0.18 indicating that Relay Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sana Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.0% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are owned by institutional investors. 5.0% of Relay Therapeutics shares are owned by company insiders. Comparatively, 25.4% of Sana Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Sana Biotechnology has lower revenue, but higher earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	239.39	-$276.48M	-$1.57	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A

Relay Therapeutics currently has a consensus price target of $24.17, indicating a potential upside of 26.00%. Sana Biotechnology has a consensus price target of $9.50, indicating a potential upside of 202.55%. Given Sana Biotechnology's higher possible upside, analysts plainly believe Sana Biotechnology is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Relay Therapeutics has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.13, indicating that its share price is 113% more volatile than the broader market.

Relay Therapeutics' return on equity of -43.94% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-43.94%	-40.11%
Sana Biotechnology	N/A	-108.01%	-40.68%

Summary

Relay Therapeutics beats Sana Biotechnology on 9 of the 15 factors compared between the two stocks.

Get Sana Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SANA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SANA vs. The Competition

Export

Metric	Sana Biotechnology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$876.62M	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-3.38	20.49	27.07	23.94
Price / Sales	N/A	300.33	515.91	90.33
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	5.23	7.92	10.43	6.14
Net Income	-$244.17M	$23.81M	$3.60B	$331.74M
7 Day Performance	-12.04%	-1.09%	-1.20%	-1.82%
1 Month Performance	-0.32%	2.56%	1.12%	-1.45%
1 Year Performance	-29.28%	42.16%	23.66%	16.32%

Sana Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SANA Sana Biotechnology	2.9415 of 5 stars	$3.14 -0.3%	$9.50 +202.5%	-32.2%	$876.62M	N/A	N/A	380	News Coverage Analyst Downgrade
NAMS NewAmsterdam Pharma	3.1984 of 5 stars	$33.28 -5.6%	$49.00 +47.2%	+33.6%	$4.12B	$22.50M	N/A	4	News Coverage Positive News Analyst Forecast
DNLI Denali Therapeutics	3.1023 of 5 stars	$26.48 +3.1%	$34.75 +31.2%	+63.6%	$4.08B	$330.53M	N/A	430
DYN Dyne Therapeutics	3.2208 of 5 stars	$23.64 +0.9%	$34.17 +44.5%	+160.0%	$3.87B	N/A	N/A	100	News Coverage Upcoming Earnings Gap Up
CPRX Catalyst Pharmaceuticals	3.923 of 5 stars	$31.48 +0.0%	$32.00 +1.7%	N/A	$3.85B	$588.99M	18.09	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SANA) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sana Biotechnology (SANA) Competitors

SANA vs. NAMS, DNLI, DYN, CPRX, and RLAY

How does Sana Biotechnology compare to NewAmsterdam Pharma?

Summary

How does Sana Biotechnology compare to Denali Therapeutics?

Summary

How does Sana Biotechnology compare to Dyne Therapeutics?

Summary

How does Sana Biotechnology compare to Catalyst Pharmaceuticals?

Summary

How does Sana Biotechnology compare to Relay Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SANA vs. The Competition

Sana Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sana Biotechnology (SANA) Competitors

SANA vs. NAMS, DNLI, DYN, CPRX, and RLAY

How does Sana Biotechnology compare to NewAmsterdam Pharma?

Which has more risk & volatility, SANA or NAMS?

Does the media prefer SANA or NAMS?

Do analysts rate SANA or NAMS?

Do insiders and institutionals have more ownership in SANA or NAMS?

Is SANA or NAMS more profitable?

Which has stronger earnings & valuation, SANA or NAMS?

Summary

How does Sana Biotechnology compare to Denali Therapeutics?

Which has stronger valuation and earnings, SANA or DNLI?

Does the media refer more to SANA or DNLI?

Do analysts prefer SANA or DNLI?

Which has more risk & volatility, SANA or DNLI?

Do insiders & institutionals have more ownership in SANA or DNLI?

Is SANA or DNLI more profitable?

Summary

How does Sana Biotechnology compare to Dyne Therapeutics?

Do analysts prefer DYN or SANA?

Is DYN or SANA more profitable?

Does the media favor DYN or SANA?

Which has stronger earnings and valuation, DYN or SANA?

Which has more risk and volatility, DYN or SANA?

Do insiders and institutionals hold more shares of DYN or SANA?

Summary

How does Sana Biotechnology compare to Catalyst Pharmaceuticals?

Is SANA or CPRX more profitable?

Do institutionals & insiders believe in SANA or CPRX?

Which has more risk and volatility, SANA or CPRX?

Which has better earnings and valuation, SANA or CPRX?

Does the media prefer SANA or CPRX?

Do analysts rate SANA or CPRX?

Summary

How does Sana Biotechnology compare to Relay Therapeutics?

Does the media favor RLAY or SANA?

Do insiders and institutionals believe in RLAY or SANA?

Which has stronger valuation and earnings, RLAY or SANA?

Do analysts prefer RLAY or SANA?

Which has more risk and volatility, RLAY or SANA?

Is RLAY or SANA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SANA vs. The Competition

Sana Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools